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RESULTS

OBJECTIVES
Table 1. Baseline characteristics of LCSP
participants

§ To determine the current reporting methods for incidental findings
and measure the frequency of clinical follow-up.

Total Cohort
(n = 1,168)
Age, years, mean ± SD
Gender, n (%)

BACKGROUND
§ The US Preventive Services Task Force (USPSTF) recommends adults
aged 55-80 with ≥30 pack-year smoking history undergo annual
screening for lung cancer with a LDCT of the chest.
§ The American College of Radiology (ACR) reports incidental
detection of liver, kidney, adrenal gland, and thyroid lesions at
incidences ranging from 3-40%. Among lung cancer screening
patients, 41–94 % have incidental findings (IFs) on LDCT, and
coronary artery calcifications (CAC) are the most common IF. CAC is
an independent predictor of cardiovascular events in post-hoc
analyses of lung cancer screening cohorts.
§ To our knowledge, there is no standardized approach to radiologic
reporting or management of IFs on LDCT at Jefferson. Appropriate
follow-up of IFs has important implications on patient health
outcomes, healthcare spending, and resource allocation.

METHODS
§ The Jefferson Lung Cancer Screening Program (LCSP) is a

centralized screening program for patients at high risk for lung
cancer based on CMS, USPSTF, and NCCN criteria.
§ Data from patients screened between Jan 2018 and February 2020
were collected prospectively (IRB control# 17D.150).
§ Patients with ≥1 IF reported on LDCT were identified, and radiology
reports and other clinical data were retrospectively reviewed.
o For patients with liver, kidney, thyroid, and adrenal gland
lesions, LDCT reports were reviewed for presence of IF and
follow-up recommendations and these were compared with
ACR guidelines.
o A subset of patients with CAC, screened between Jan 2018 and
April 2019, were reviewed for history of atherosclerotic
cardiovascular disease (ASCVD), cardiac medications,
cardiovascular workup, and presence of cardiology evaluation.
1,168 patients were screened between
Jan 2018 and Feb 2020

Figure 1. CONSORT Diagram. Clinical
data for patients undergoing LDCT for
lung cancer screening were reviewed
for presence of IFs and follow-up.

384 patients had incidental liver lesions, kidney
lesions, thyroid lesions, or adrenal gland lesions

Clinical data for 328 patients with liver cysts or
nodules, kidney cysts, thyroid nodules, or adrenal gland
lesions were reviewed

64.37 ± 5.81

427 patients had CAC
detected on LDCT between
Jan 2018 – April 2019

Clinical data for 40 patients
with severe CAC were
reviewed

Male

492 (42.1%)

Female

676 (57.9%)

Race, n (%)
White

635 (54.4%)

Black or African American

468 (40.1%)

Asian
Other races
BMI, mean ± SD

59 (5.1%)
6 (0.5%)
29.29 ± 6.81

Smoking status, n (%)
Former

527 (45.1%)

Current

641 (54.9%)

Smoking pack-years, mean ± SD

53.68 ± 24.58

Finding
n (%)
Coronary artery
876 (75.0%)
calcifications
Mild
484 (41.4%)
Moderate
294 (25.2%)
Severe
98 (8.4%)
Emphysema
675 (57.8%)
Atherosclerosis
415 (35.5%)
Liver findings*
141 (12.1%)
Kidney findings*
108 (9.3%)
Thyroid findings*
86 (7.4%)
Adrenal gland lesions*
49 (4.2%)
*Liver findings included: nodules, cysts,
calcifications, hemangiomas, steatosis, and
cirrhosis. Kidney findings included: cysts
and calculi. Thyroid findings included:
nodules and thyroid enlargement. Adrenal
findings included: adenomas and
calcifications.

Table 3. Incidental findings and radiologic recommendations for follow-up
Liver cysts or
nodules
n= 107
n (%)
Stable or benign radiographic
features noted in report
Follow-up recommendations
provided in report
No recommendation reported,
but follow-up indicated by
ACR guidelines

15

Table 2. Frequency of incidental
findings on LDCT

Kidney cysts
n= 99
n (%)

Thyroid
nodules
n= 73
n (%)

Adrenal gland
lesions
n= 49
n (%)

48 (44.9%)

27 (27.3%)

21 (28.8%)

36 (73.5%)

2 (1.9%)

5 (5.1%)

13 (17.8%)

1 (2.0%)

6 (5.6%)

- -

3 (4.1%)

4 (8.2%)

Table 4. Baseline characteristics of patients with severe CAC detected on LDCT
(n=40, Jan 2018-April 2019 cohort)
Patients seen
by a
cardiologist,
n= 23
67.8 ± 5.6

Patients not seen*
by a cardiologist,
n= 17

Not Treated by Cardiologist (n=17)

10

5

0
Cardiac
Medication Dose
Change

Stress Test

Echocardiogram

Coronary
Angiography

Cardiac
Cardiac Deaths
Hospitalizations

Figure 2. Management, subsequent testing and cardiac events among patients
with severe CAC detected on LDCT (n= 40, Jan 2018-April 2019 cohort).
Patients seen by a cardiologist received medication changes and underwent
additional testing more frequently than those who were not seen by a
cardiologist within 6 months of CAC identification on LDCT.

DISCUSSION
§ The occurrence of incidental findings on LDCT for lung cancer
screening was common, with 75% of screened patients
demonstrating some degree of CAC (Table 2). Extrathoracic IFs
included liver, kidney, thyroid, and adrenal glad lesions.
§ Among LDCT scans with extrathoracic IFs, follow-up
recommendations were included in radiology reports in a minority
of cases (1.9-17.8%). Specifically, 13 incidental findings warranted
follow-up by ACR guidelines, but no recommendations were
reported (Table 3).
§ Patients with severe CAC detected on LDCT for lung cancer
screening have a high incidence of previously known ASCVD (Table
4). Patients referred to Cardiology undergo subsequent procedures
at a significantly higher rate than patients with severe CAC not
seen by a cardiologist (p<0.001) (Figure 2).

p-value

Age, y ± SD
66.4 ± 3.6
0.318
Sex
0.088
Male, n(%)
10 (43.5%)
12 (70.6%)
Female, n(%)
13 (56.5%)
5 (29.4%)
Race
0.085
White, n(%)
13 (56.5%)
14 (82.4%)
Black, n(%)
10 (43.5%)
3 (17.6%)
Smoking status
0.131
Current smoker, n(%)
15 (65.2%)
7 (41.2%)
Former smoker, n(%)
8 (34.8%)
10 (58.8%)
Cardiovascular history
Known ASCVD#, n(%)
19 (82.6%)
9 (52.9%)
0.043
Patients on statin therapy at baseline, n(%)
21 (91.3%)
14 (82.4%)
0.634
Prior coronary stent or CABG, n(%)
11 (47.8%)
4 (23.5%)
0.117
Patients with a cardiologist prior to LDCT, n(%)
18 (78.3%)
5 (29.4%)
0.002
*within up to 6 months of follow-up time after LDCT
#Atherosclerotic cardiovascular disease (ASCVD) includes: coronary heart disease (angina, MI, HF);
cerebrovascular disease (CVA/ TIA); peripheral artery disease; aortic atherosclerosis or aortic
aneurysm

Management and outcomes among patients with severe CAC
Treated by Cardiologist (n=23)

Number of patients

§ To define the frequency of incidental findings on low-dose CT
(LDCT) scans among patients undergoing lung cancer screening.

CONCLUSIONS and FUTURE DIRECTIONS
§ Our data demonstrate variability in radiologic reporting of IFs
detected on screening LDCTs and in clinical follow-up of IFs.
§ Inconsistent communication of incidental findings and their
clinical relevance may lead to increased healthcare costs,
unnecessary radiation exposure and procedures, and/or missed
opportunity for intervention.
§ Future directions include distribution of standardized guidelines
for workup of IFs to accompany LDCT reporting to primary care
providers, followed by reassessment of IF management.
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